MK-1167

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Alzheimer DiseaseAlzheimer's DiseaseAlzheimer’s disease dementiaDementiaHealthy

Phase 1

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

CompletedNCT06285240

Merck Sharp & Dohme LLCAlzheimer's Disease

Start: 2024-03-28End: 2024-09-23Updated: 2025-10-14

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

CompletedNCT06625840

Merck Sharp & Dohme LLCHealthy

Start: 2023-09-18End: 2024-05-08Updated: 2024-10-03

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

CompletedNCT06703463

Merck Sharp & Dohme LLCHealthy

Start: 2023-10-17End: 2024-02-02Updated: 2024-11-25

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

CompletedNCT07266818

Merck Sharp & Dohme LLCHealthy

Start: 2025-12-18End: 2026-04-09Updated: 2026-04-28

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

CompletedNCT07334860

Merck Sharp & Dohme LLCHealthy

Start: 2026-02-06End: 2026-05-20Updated: 2026-06-15

Phase 2

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

TerminatedNCT06721156

Merck Sharp & Dohme LLCAlzheimer Disease, Dementia

Start: 2024-12-16End: 2026-06-05Updated: 2026-07-01

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

RecruitingCTIS2024-515539-31-00

Merck Sharp & Dohme LLCAlzheimer’s disease dementia

Start: 2025-04-01Target: 79Updated: 2025-12-11